Tokyo-based Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Pulmagen Therapeutics (Asthma) Limited, a UK-based drug development company, announce today an exclusive licensing agreement granting Teijin Pharma the rights to develop, manufacture and market ADC3680, a bronchial asthma therapeutic discovered by Pulmagen Therapeutics, in Japan.